Skip to main content
Enter your The Contraceptive Pipeline Database username.
Enter the password that accompanies your username.
Depo-subQ + Uniject
SRA/WHO PQ Approved
Sayana Press contains 104 mg of depot medroxyprogesterone acetate (DMPA) per 0.65 mL dose and is administered via subcutaneous (SC) injection using the Uniject™ injection system, a small pre-filled single use device.
July 26, 2016
Active Pharmaceutical Ingredient (API):
Potential Multi-Purpose Technology (MPT):
one injection every 3 months
Pfizer registered depo-subQ provera 104™, the same drug in Sayana Press, with the US FDA in 2004. Sayana and Sayana Press are also registered with the UK Medicines and Healthcare Products Regulatory Agency (MHRA). It was approved in the European Union via procedure number UK/H/0960/002UK/H/0960/002.
Sayana Press is being introduced into Bangladesh, Burkina Faso, Niger, Senegal, and Uganda in 2014.
Administration via Uniject would allow for community-based or home-based administration. It has been approved for self-injection in the United Kingdom.
New formulation allows for 30% lower dose of progestin compared to DMPA IM.
Frequently Asked Questions About Sayana® Press
. July 2014.
Download Product Report